Director of Molecular Pharmacology
B.A., UC Santa Cruz, Santa Cruz, California, 1991
American Society of Clinical Oncology
International Association for the Study of Lung Cancer
Southwest Oncology Group
Honors and Awards:
Select Recent Publications:
Bai L, Yang JC, Ok JH, Mack PC, Kung HJ, Evans CP. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration. Int J Cancer. 2011 Jul 25. doi: 10.1002/ijc.26303.
Chew HK, Somlo G, Mack PC, Gitlitz B, Gandour-Edwards R, Christensen S, Linden H, Solis LJ, Yang X, Davies AM. Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors. Ann Oncol. 2011 Jul 21.
Chinn DC, Holland WS, Yoon JM, Zwerdling T, Mack PC. Anti-tumor activity of the HSP90 inhibitor SNX-2112 in pediatric cancer cell lines. Pediatr Blood Cancer. 2011 Jul 27. doi: 10.1002/pbc.23270.
Holland WS, Tepper CG, Pietri JE, Chinn DC, Gandara DR, Mack PC, Lara PN Jr. Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy. Cancer Chemother Pharmacol. 2011 Jun 5.
Gandara DR, Grimminger P, Mack PC, Lara PN Jr, Li T, Danenberg PV, Danenberg KD. Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer. J Thorac Oncol. 2010. Epub 2010 Oct 4.
Herbst RS, Kelly K, Chansky K, Mack PC, Franklin WA, Hirsch FR, Atkins JN, Dakhil SR, Albain KS, Kim ES, Redman M, Crowley JJ, Gandara DR. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. J Clin Oncol. 2010 Nov 1;28(31):4747-54.
2009 Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, Teramukai S, Ohe Y, Kubota K, Williamson SK, Gautschi 0, Lenz HJ, McLeod HL, Lara PN, Coltman CA, Fukuoka M, Saijo N, Fukushima M, Mack PC. Japan-USA common arm analysis of pad itaxelcarboplatin in advanced non-small cell lung cancer: a model for assessing population-related pharmacogenomics. Journal of Clin Oncol. 27:3540-3546.
2009 McCall JL, Burich RA, Mack Pc. GCP, a genistein-rich compound, inhibits proliferation and induces apoptosis in lymphoma cell lines. Leuk Res, 2009 Apr 24.
2009 Mack PC, Holland WS, Burich RA, Sangha R, Solis LJ, Li Y, Beckett LA, Lara PN Jr., Davies AM, Gandara DR. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. J Thorac Oncol. 2008 Oct 10;26(29):4771-6. Epub 2008 Sep 8.
2008 Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN Jr., Franklin WA, Le Q-T, Crowley JJ and Gandara DR. Lower Osteopontin Plasma Levels are Associated with Superior Outcomes Following Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer Patients: Southwest Oncology Group Trial S0003. Journal of Clinical Oncology, 26(29):4771-4776, 2008.